Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

Regeneron's bid to acquire the bankrupt genetic testing firm 23andMe for $256 million has likely come to an end.

The consumer privacy ombudsman in 23andMe’s sale of customers’ genetic data is defending his choice of counsel against ...

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

Now that the data is going to a 23andMe-adjacent nonprofit, which is also making similar promises, I guess nothing much has ...

The DNA data of millions of people who used 23andMe's services won't be sold to a pharmaceutical company. A bankruptcy judge ...

Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company ...

A bankruptcy court gave the green light for TTAM Research Institute - a firm launched by 23andMe's co-founder and former CEO ...

Regeneron had previously planned to keep on all of the company's employees and continue offering consumer DNA testing kits. Besides answering customers' questions about their ancestry, 23andMe's ...

Me Holding said Tuesday that a U.S. bankruptcy court has approved the sale of “substantially all” its assets to TTAM Research ...